Historic Go-Ahead For Malaria Vaccine To Protect African Children
The title of this post, is the same as that of this article on the BBC.
This is the first paragraph.
Children across much of Africa are to be vaccinated against malaria in a historic moment in the fight against the deadly disease.
The vaccine has been developed by GSK, who have their headquarters on the Golden Mile in Brentford.
The vaccine is called RTS,S and is described like this in the first paragraph of its Wikipedia entry.
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine.
Approved for use by European regulators in July 2015, it is the world’s first licensed malaria vaccine and also the first vaccine licensed for use against a human parasitic disease of any kind. The RTS,S vaccine was conceived of and created in the late 1980s by scientists working at SmithKline Beecham Biologicals (now GlaxoSmithKline Vaccines) laboratories in Belgium. The vaccine was further developed through a collaboration between GSK and the Walter Reed Army Institute of Research and has been funded in part by the PATH Malaria Vaccine Initiative and the Bill and Melinda Gates Foundation. Its efficacy ranges from 26 to 50% in infants and young children. On 23 October 2015, the World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Committee (MPAC) jointly recommended a pilot implementation of the vaccine in Africa.
When you consider how fast the Covid-19 vaccines were developed, this might appear to have taken a long time to be developed. But then as Wikipedia states, “this is the first vaccine licensed for use against a human parasitic disease of any kind.”
I can’t describe this as anything other than good news.
The Anonymous Widower 
It is extremely good news, and hopefully will save the lives of many children.
Comment by nosnikrapzil | October 7, 2021 |